Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 553001 | ISIN: IL0010852080 | Ticker-Symbol: CW9
Tradegate
27.03.24
17:02 Uhr
2,360 Euro
-0,040
-1,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COMPUGEN LTD Chart 1 Jahr
5-Tage-Chart
COMPUGEN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
2,3602,44028.03.

Aktuelle News zur COMPUGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.Compugen Ltd reports results for the quarter ended in December - Earnings Summary4
05.03.COMPUGEN LTD - 20-F, Annual and transition report of foreign private issuers1
05.03.Compugen: EPS übertrifft Schätzungen - Umsatz besser als erwartet10
05.03.Compugen GAAP EPS of $0.11 beats by $0.01, revenue of $33.46M beats by $13.46M5
05.03.Compugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2023 Results143Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple...
► Artikel lesen
05.03.COMPUGEN LTD - 6-K, Report of foreign issuer1
04.03.Earnings Preview For Compugen9
04.03.Compugen Q4 2023 Earnings Preview1
15.02.Compugen Appoints Mahler As Chief Medical Officer2
15.02.COMPUGEN LTD - 6-K, Report of foreign issuer1
15.02.Compugen Ltd.: Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer223HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
► Artikel lesen
30.01.Compugen, Iterum Therapeutics among healthcare movers6
30.01.CLS, CGEN and RCUS are among pre market gainers5
08.01.Compugen regains compliance with Nasdaq's minimum bid price requirement7
08.01.Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial295LONDON (dpa-AFX) - Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca...
► Artikel lesen
08.01.COMPUGEN LTD - 6-K, Report of foreign issuer1
08.01.Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer602HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
► Artikel lesen
08.01.Compugen Ltd.: Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement191HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
► Artikel lesen
21.12.23Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More13
20.12.23Gilead (GILD), Compugen Collaborate for Immunotherapy Program8
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1